Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mutations in haemophilia A

R Schwaab1, J Oldenburg, E G Tuddenham

  • 1Institute of Experimental Haematology and Blood Transfusion, Bonn, Germany.

British Journal of Haematology
|March 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Platelets are a safe way to deliver factor VIII. After 13 years of preclinical research it is now time for a clinical trial.

Journal of thrombosis and haemostasis : JTH·2016
Same author

Pharmacokinetic properties of two factor VIII concentrates with single and double viral inactivation.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Long-term surveillance for human anti-murine antibodies of a group of haemophiliacs treated only with immunoaffinity-purified FVIII concentrates.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

No increased bleeding risk for oral surgery in patients with severe congenital bleeding disorders due to intense perioperative management.

Oral and maxillofacial surgery·2014
Same author

Spotlight on the human factor: building a foundation for the future of haemophilia A management: report from a symposium on human recombinant FVIII at the World Federation of Hemophilia World Congress, Melbourne, Australia on 12 May 2014.

Haemophilia : the official journal of the World Federation of Hemophilia·2014
Same author

Controlled, cross-sectional MRI evaluation of joint status in severe haemophilia A patients treated with prophylaxis vs. on demand.

Haemophilia : the official journal of the World Federation of Hemophilia·2014

Researchers identified 14 mutations, including novel deletions and point mutations, in 281 haemophilia A patients. These genetic alterations correlate with disease severity and inhibitor development, offering insights into haemophilia A genetics.

Area of Science:

  • Genetics
  • Molecular Biology
  • Hematology

Background:

  • Haemophilia A is a genetic bleeding disorder caused by mutations in the Factor VIII gene.
  • Identifying specific mutations is crucial for understanding disease mechanisms and developing targeted therapies.

Purpose of the Study:

  • To identify and characterize mutations in the Factor VIII gene in a cohort of haemophilia A patients.
  • To correlate identified mutations with clinical phenotypes, including disease severity and inhibitor formation.

Main Methods:

  • DNA analysis of 281 unrelated haemophilia A patients using Southern blotting.
  • Utilized cloned factor VIII cDNA probes and genomic fragments with restriction enzymes to detect mutations.
  • Sequencing of deletion breakpoints for detailed characterization.

Related Experiment Videos

Main Results:

  • Identified 14 mutations: six novel partial Factor VIII gene deletions (exons 1, 6, 16, 26) and eight point mutations (exons 18, 24, 26).
  • Nonsense mutations (C-->T) and missense mutations (G-->A, G-->T) were identified, altering protein function.
  • Deletions and most point mutations were associated with severe haemophilia A and inhibitor development; one G-->A mutation linked to mild disease also had an inhibitor.

Conclusions:

  • The study identified a spectrum of Factor VIII gene mutations in haemophilia A patients, highlighting deletions and point mutations as key genetic drivers.
  • Mutation type and location significantly correlate with disease severity and the potential for inhibitor development.
  • Genetic analysis provides valuable insights into the molecular basis of haemophilia A, aiding in understanding genotype-phenotype correlations.